MEHLMAN CONSULTING, INC.

Lobbying for ULTRAGENYX PHARMACEUTICAL, INC. · Biopharmaceutical Company

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 17, 2026

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

California

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

Lobbying activity 2

Health Issues

Issues relating to rare disease and patient access. H.R.1262/S. 932 - Give Kids a Chance Act of 2025.

Budget/Appropriations

FY 2027 Appropriations.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.